{"entity":{"id":"nct05458297","kind":"trial","name":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-","aka":[],"tldr":"A phase 2 trial of Zilovertamab vedotin, Nemtabrutinib in mantle cell lymphoma and follicular lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) is a phase 2 interventional study registered as NCT05458297 by Merck Sharp & Dohme LLC, with 189 participants planned, started 2022-07-21 and due to reach its primary completion in 2029-05-17. Interventions recorded: Zilovertamab vedotin, Nemtabrutinib. Conditions listed: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05458297","url":"https://clinicaltrials.gov/study/NCT05458297"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma","follicular-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["zilovertamab-vedotin","nemtabrutinib"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05458297","phase":"2","setting":"A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)","sponsor":"Merck Sharp & Dohme LLC","enrolled":189,"outcomes":[]},"route":"/trials/nct05458297/","neighbours":{"cancer":[{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"drug":[{"id":"nemtabrutinib","kind":"drug","name":"Nemtabrutinib","route":"/drugs/nemtabrutinib/"},{"id":"zilovertamab-vedotin","kind":"drug","name":"Zilovertamab vedotin","route":"/drugs/zilovertamab-vedotin/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}